Health and effects
Cannabinoids and NREM sleep
What studies can tell us about cannabinoids and NREM sleep, including human research, early evidence, and important limits.
The short answer
What does the research say about NREM sleep?
Researchers have studied cannabinoids in connection with NREM sleep. The current literature covers CBN and Oleamide. This page brings together 2 human-study sources and 1 lab, animal, or mechanism source. It includes 7 specific study findings from 2 sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1
Key takeaways
What to know first
- 1
Research on NREM sleep covers CBN and Oleamide; those areas should not be combined into one claim. 1
- 2
The source set includes human research as well as earlier-stage studies. 2
- 3
Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3
Research areas
What researchers studied about NREM sleep
These are the main questions represented in the current literature. Each link opens a source used to build the overview.
Mostly preclinical
CBN
Researchers have studied CBN in connection with NREM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 1
Too limited for a firm answer
Oleamide
Researchers have studied Oleamide in connection with NREM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3
Results extracted so far
What did the studies report?
These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.
-
In a rat polysomnography study, researchers reported more total sleep time. This does not establish the same result in people. 1
-
In a rat polysomnography study, researchers reported more NREM sleep. This does not establish the same result in people. 1
-
In a rat polysomnography study, researchers reported more REM sleep. This does not establish the same result in people. 1
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers did not detect a difference in wake after sleep onset following a single oral dose of 30 mg or 300 mg CBN. The recorded comparator was placebo. 2
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported shorter sleep onset latency following 300 mg CBN. The recorded comparator was placebo. 2
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported higher subjective sleep quality following 300 mg CBN. The recorded comparator was placebo. 2
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported more NREM-2 sleep following 300 mg CBN. The recorded comparator was placebo. 2
How strong is the research?
Not every study answers the same question
This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.
Human studies
Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.
Reviews and evidence summaries
Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.
Lab, animal, and mechanism research
Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.
Another 1 of 4 research source could not be placed cleanly into those three groups from the recorded study details.
What these studies actually looked at
The research on NREM sleep is not one kind of study. This source set includes 2 clinical studies in people, 1 mechanism-focused study, and 1 rat polysomnography study. 3
The recorded populations or models include 20 adults with physician-diagnosed insomnia disorder (1 source), people or patients (1 source), and rats (1 source). A result from one group or model should not be assumed to apply to another. 4
The most common recorded outcome focus is nREM sleep (1 source), oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms (1 source), and polysomnography NREM-2 sleep (1 source). Closely related outcome names can still describe different measurements. 1
Some source records specify doses including 300 mg CBN (1 source) and single oral dose of 30 mg or 300 mg CBN (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 2
The NREM sleep source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 3
Examples from the literature
What did the studies actually look at?
Each example names the research question and the study details recorded for that source.
rat polysomnography study
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
On this page, this source examines CBN and total sleep time, CBN and nREM sleep, and CBN and rEM sleep and other related questions. 1
- Study type
- rat polysomnography study and mechanism-focused study
- Population or model
- rats
- Outcome focus
- total sleep time and nREM sleep and other recorded details
- Evidence stage
- preclinical research and mechanism-focused research
clinical study in people
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
On this page, this source examines CBN and wake after sleep onset, CBN and sleep onset latency, and CBN and subjective sleep quality and other related questions. 2
- Study type
- clinical study in people
- Population or model
- 20 adults with physician-diagnosed insomnia disorder
- Outcome focus
- polysomnography wake after sleep onset and sleep onset latency and other recorded details
- Dose recorded
- single oral dose of 30 mg or 300 mg CBN and 300 mg CBN
- Evidence stage
- human research
evidence still limited
Cannabinoids and Sleep/Wake Control.
On this page, this source examines Oleamide and oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms. 3
- Outcome focus
- oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms
- Evidence stage
- evidence still limited
clinical study in people
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.
On this page, this source examines CBN and sleep. 4
- Study type
- clinical study in people
- Population or model
- people or patients
- Outcome focus
- sleep-related outcomes
- Evidence stage
- evidence still limited
Safety and limits
What should readers keep in mind?
Research on NREM sleep should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3
Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.
Common questions
Questions people ask
Can cannabinoids help with NREM sleep?
Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 3
Why can studies reach different answers?
Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 4
What should I check in a study?
Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 1
Sources
Read the research
The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.
-
1
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research PubMed 39528623 DOI 10.1038/s41386-024-02018-7
-
2
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research PubMed 41698831 DOI 10.1111/jsr.70284
-
3
Cannabinoids and Sleep/Wake Control. evidence still limited PubMed 33537938 DOI 10.1007/978-3-030-61663-2_6
-
4
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited PubMed 37612115 DOI 10.1136/bmjopen-2022-071148
See all 4 research sources
This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.
- Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research / 4 linked research notes PubMed 41698831
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research / 4 linked research notes PubMed 39528623
- Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited / 1 linked research note PubMed 37612115
- Cannabinoids and Sleep/Wake Control. evidence still limited / 1 linked research note PubMed 33537938